Vivanza Biosciences logo

Vivanza Biosciences financials: balance sheet, profit and loss, cash flow

BSE: 530057Pharmaceuticals & BiotechnologySmall Cap

Vivanza Biosciences Limited · Face value ₹1 · Listed May 1995
Last close ₹1.43down ₹0.07 (4.67%)

Share price at the BSE close on 29 Oct 2026. Previous close ₹1.50.

29 Oct: open ₹1.50, high ₹1.50, low ₹1.43

52-week range of traded prices to 29 Oct 2026
₹1.30Low, 26 Oct 2026₹2.72High, 17 Nov 2025
Market cap
₹5.72 Cr4,790th largest listed
P/E
12.60
P/B
1.31
Dividend yield
Nonein the last 12 months
ROE
10.9%
ROCE
3.3%
Debt to equity
2.34
Volume, BSE
18,847

Vivanza Biosciences' financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Vivanza Biosciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
3.5−0.3Mar 176.40.2Mar 182.7−0.41.5Mar 199.6−0.20.4Mar 209.90.10.4Mar 21100.32.8Mar 22180.68.0Mar 23280.55.2Mar 247.4−0.78.7Mar 251160.410Mar 26
Peak revenue ₹116 Cr, year to Mar 2026; lowest ₹2.66 Cr, year to Mar 2019Back to profit in the year to Mar 2026, ₹0.39 Cr

Operating and net margin, per cent

  • Operating margin
  • Net margin
3.8%−16.6%−0.8%−3.5%1.0%−0.8%3.7%3.8%−4.9%0.6%−8.9%3.2%−16.6%−2.1%0.8%3.2%3.4%2.0%−9.1%0.3%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue116
  2. Materials and goods−114
  3. Employee costs−0.5
  4. Other expenses−0.3
  5. Operating profit0.7
  6. Depreciation0.0
  7. Other income+0.1
  8. One-off items0.0
  9. Finance costs−0.3
  10. Profit before tax0.5
  11. Tax−0.1
  12. Net profit0.4

What the company owns

  • Receivables₹12 Cr
  • Plant, investments and other assets₹6 Cr
  • Inventory₹4 Cr
  • Cash and bank₹0 Cr

What pays for it: net worth and liabilities

  • Borrowings₹10 Cr
  • Owed to suppliers₹7 Cr
  • Net worth₹4 Cr
  • Other liabilities₹0 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Vivanza Biosciences quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 7 MayJun 2026Twelve monthsFiled 7 Aug
Revenue from operations36310101018287116116
––310101017278115116
Materials and goods bought562991017267114115
Employee costs––000000100
Other expenses––000100000
Operating profit before depreciation––000011011
Operating margin––−0.8%−3.5%1.0%−0.8%3.7%3.8%−4.9%0.6%0.4%
Materials, % of revenue––88.7%96.6%92.6%92.8%92.7%93.2%91.9%98.7%99.0%
Employee costs, % of revenue––5.2%3.1%3.4%2.8%2.0%1.6%7.7%0.4%0.4%
Other expenses, % of revenue––7.0%3.9%3.0%5.1%1.6%1.3%5.2%0.2%0.2%
Depreciation and amortisation––000000000
Operating profit after depreciation––000011010
Other income00011100000
Finance costs00000000000
One-off items00000000000
Profit before tax00000011−111
00000000000
Net profit00000011−100
Other comprehensive income––000000−100
Total comprehensive income––000011−100
Net margin−8.9%3.2%−16.6%−2.1%0.8%3.2%3.4%2.0%−9.1%0.3%0.4%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2017 and Mar 2018: the statement does not state its depreciation, which operating profit is worked out from, so operating profit is not given.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 7 May
3.33.13.23.54.14.64.04.4
Share capital4.04.04.04.04.04.04.04.0
Reserves−0.7−0.9−0.8−0.50.10.60.00.4
1.50.40.42.88.05.28.710.2
6.79.15.36.717.012.29.216.9
0.60.20.02.61.42.73.30.9
Total assets10.612.48.412.822.519.516.522.1
3.53.23.43.12.93.84.13.0
7.19.15.09.719.615.712.419.1
Net debt4.53.23.55.57.95.08.510.1
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 7 May
−0.742.47−0.952.04−2.50−1.26
−0.232.06−0.832.19−2.49−1.11
−0.15−0.88−1.971.07−2.19−1.96
Receivables0.29−1.59−4.640.943.48−4.32
Inventories0.31−1.77−0.050.47−0.26−1.29
Payables−4.281.624.06−1.31−5.624.58
Other working capital3.530.87−1.340.980.20−0.92
Tax paid−0.050.00−0.12−0.15−0.01−0.15
Interest paid−0.470.410.000.000.000.00
Capital spending0.020.000.000.040.010.12
Free cash flow−0.762.47−0.952.01−2.51−1.38
Cash from investing−0.020.000.00−0.04−0.01−0.05
0.45−2.061.03−1.982.461.26
Dividends paid0.000.000.000.000.000.00
Shares bought back0.000.000.000.000.000.00
Shares issued0.000.000.000.000.000.00
Net change in cash−0.320.410.090.03−0.05−0.05
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 7 May
−₹0.08₹0.05−₹0.11−₹0.05₹0.02₹0.08₹1.50₹0.14−₹0.17₹0.10
As stated that year−₹0.78₹0.51−₹1.10−₹0.51₹0.19₹0.83₹1.50₹0.14−₹0.17₹0.10
−₹0.08₹0.05−₹0.11−₹0.05₹0.02₹0.08₹1.50₹0.14−₹0.17₹0.10
––₹0.82₹0.77₹0.79₹0.87₹1.02₹1.16₹0.99₹1.09
Shareholder yield––––0.0%0.0%0.0%0.0%0.0%0.0%
Market cap at the year end (₹ crore)48.428.0––52.275.575.227.28.07.0
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Consolidated, years to March.Vivanza Biosciences PE ratio and valuation

RatioMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 7 May
Revenue growth85.3%−58.7%261.8%2.8%5.2%71.2%56.3%−73.3%1,461.4%
Operating profit growth––––––61.0%––
Net profit growth––––346.8%79.7%−8.5%––
Earnings per share growth––––336.8%1,707.2%−90.7%––
–−13.4%−6.5%2.4%10.0%15.8%12.5%−15.7%9.5%
––7.0 pts8.8 pts7.6 pts5.8 pts−3.2 pts−28.2 pts25.1 pts
From the net margin––11.7 pts8.7 pts7.8 pts0.5 pts−6.5 pts−70.5 pts16.3 pts
From asset turnover––−4.0 pts0.3 pts0.3 pts0.3 pts2.9 pts39.9 pts8.0 pts
From borrowing––−0.7 pts−0.2 pts−0.4 pts4.9 pts0.4 pts2.4 pts0.9 pts
Return on capital employed–−0.5%−9.8%2.4%−1.4%5.5%10.7%−3.0%4.9%
Cash conversion–––−995.3%740.8%−158.0%373.4%–−319.5%
Interest cover–––0.2–1.62.6–2.5
Debt to equity–0.450.130.110.791.951.112.182.34
Receivable days–70724823127525615139639
Inventory days–310382692552812111
Payable days–87932015420721111614023
Cash conversion cycle, days–138−34103160996437727
Working capital days–5931151172051857741536
Asset turnover–0.250.840.950.981.011.330.416.02
Assets per rupee of net worth–3.213.603.333.204.664.814.184.63
Sales per rupee of plant–3.9214.1914.3415.2526.2139.4910.62144.65
Capital spending to depreciation–––2.150.000.003.100.565.74
Plant being built, % of plant in use––0.0%0.0%0.0%–0.0%0.0%0.0%
Interest cover is left blank for the years to Mar 2019, Mar 2020, Mar 2022 and Mar 2025: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
2.0%
Cash from operations against operating profit
−171.9%
Measure10 years5 years3 years
Revenue growth, yearly rate–63.6%86.7%
Profit growth, yearly rate–39.5%−13.0%
Return on equity, average–6.4%2.1%
Return on capital employed, average–3.3%4.2%
Operating margin, average–0.5%−0.1%
Net margin, average−2.4%0.0%−2.3%
Asset turnover, average–1.952.58
Cash conversion cycle, days, average–145156
Interest cover, average––2.6
Debt to equity, average–1.681.88

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−0.19−1.72−1.26
Cash from investing−0.10−0.10−0.05
Cash from financing0.711.741.26
Capital spending0.170.170.12
Dividends paid0.000.000.00
Shares bought back0.000.000.00
Shares issued for cash0.000.000.00
Borrowings raised–1.541.54
Borrowings repaid7.786.910.00

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––576535
Altman Z-scorePublished threshold 1.81–––7.15–3.562.981.005.75
Beneish M-scorePublished threshold −1.78–––−2.18−3.23−1.65−2.43−1.7612.78
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––8.05−20.068.75−6.9510.208.85
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––0.772.41−2.97−6.41
Receivables growth less revenue growthOur threshold 0 percentage points––−234.89−7.1920.26−12.05−63.8543.17−1,407.79
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––−345.84−30.95266.07−69.07−76.1486.52−1,520.76
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––0.00−0.370.490.720.28−1.410.04
Assets under construction, years of additionsOur threshold 2 years of additions–––0.00––0.000.000.00
Effective tax ratePublished threshold 17.16 per cent11.97––39.620.1216.4821.27–27.48
Tax charged less tax paid, % of profitOur threshold 10 percentage points––––−0.210.01−0.16–0.17
A threshold marked as ours has no published figure; it is the line we read the check against.